Log in

Nantkwest Stock Forecast, Price & News

+0.16 (+1.92 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $8.49
50-Day Range
MA: $8.51
52-Week Range
Now: $8.49
Volume1.63 million shs
Average Volume1.94 million shs
Market Capitalization$916.67 million
P/E RatioN/A
Dividend YieldN/A
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More
Nantkwest logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic



Sales & Book Value

Annual Sales$40,000.00
Price / Sales22,916.63
Book Value$1.23 per share


Net Income$-65,790,000.00
Net Margins-162,086.03%


Market Cap$916.67 million
Next Earnings Date11/3/2020 (Estimated)
+0.16 (+1.92 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nantkwest (NASDAQ:NK) Frequently Asked Questions

How has Nantkwest's stock price been impacted by Coronavirus (COVID-19)?

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NK stock has increased by 141.2% and is now trading at $8.49.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Nantkwest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nantkwest

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Nantkwest

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings results on Friday, August, 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. Nantkwest had a negative net margin of 162,086.03% and a negative return on equity of 52.71%.
View Nantkwest's earnings history

What price target have analysts set for NK?

1 brokers have issued 1 year price objectives for Nantkwest's shares. Their forecasts range from $18.00 to $18.00. On average, they expect Nantkwest's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price.
View analysts' price targets for Nantkwest

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Who are Nantkwest's key executives?

Nantkwest's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
  • Mr. Richard J. Tajak, Consultant (Age 66)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.61%), Charles Schwab Investment Management Inc. (0.19%), Bank of New York Mellon Corp (0.18%), Nuveen Asset Management LLC (0.10%), Meridian Investment Counsel Inc. (0.10%) and California Public Employees Retirement System (0.06%). Company insiders that own Nantkwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Steve Gorlin.
View institutional ownership trends for Nantkwest

Which major investors are selling Nantkwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, and Bridgeway Capital Management Inc.. Company insiders that have sold Nantkwest company stock in the last year include Barry J Simon, Frederick W Driscoll, and John C Thomas.
View insider buying and selling activity for Nantkwest

Which major investors are buying Nantkwest stock?

NK stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Meridian Investment Counsel Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, Nantahala Capital Management LLC, Schonfeld Strategic Advisors LLC, and State of Wisconsin Investment Board.
View insider buying and selling activity for Nantkwest

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $8.49.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $916.67 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.